Europe’s medical devices industry saw a rise of 27.9% in overall deal activity during Q3 2020, when compared to the four-quarter average, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 110 deals worth $1.49bn were announced for the region during Q3 2020, against the last four-quarter average of 86 deals.
Of all the deal types, venture financing saw most activity in Q3 2020 with 57, representing a 51.8% share for the region.
In second place was M&A with 35 deals, followed by private equity deals with 18 transactions, respectively capturing a 31.8% and 16.4% share of the overall deal activity for the quarter.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn terms of value of deals, M&A was the leading category in Europe’s medical devices industry with $646.27m, while private equity and venture financing deals totalled $430.65m and $412.84m, respectively.
Europe medical devices industry deals in Q3 2020: Top deals
The top five medical devices deals accounted for 41.1% of the overall value during Q3 2020.
The combined value of the top five medical devices deals stood at $611.94m, against the overall value of $1.49bn recorded for the quarter.
The top five medical devices industry deals of Q3 2020 tracked by GlobalData were:
1) Medtronic‘s $187.06m acquisition of MEDICREA Group
2) The $118.41m private equity deal with avateramedical by Tennor Holding
3) Sulzer‘s $117.95m acquisition of Haselmeier
4) The $95.31m acquisition of Scienion by Cellink
5) Eurazeo China Acceleration Fund’s private equity deal with Dutch Ophthalmic Research Center International for $93.22m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
